5 Key BioPharma Movers That Cannot Be Ignored

Health and Healthcare

Published: December 12, 2015 10:25 am

Last Updated: January 13, 2020 4:09 pm

Over the past week, a few biotech companies made absolutely massive runs. In the past year, the health care sector was on fire from positive trials, U.S. Food and Drug Administration (FDA) approvals and mergers and acquisitions.

The companies 24/7 Wall St. has picked stood out from the rest with incredible gains or losses over the course of the past week. We have included information about each company, as well as recent trading activity and the consensus price target.

Idera Pharmaceuticals

Following the presentation of its clinical data last weekend, Idera Pharmaceuticals Inc. (NASDAQ: IDRA) made a strong push in Monday’s session. The company presented initial clinical data from its ongoing Phase 1/2 clinical trial for IMO-8400, which is being evaluated for the treatment of patients with relapsed or refractory Waldenström’s macroglobulinemia.

The primary objectives of the study were to assess safety and tolerability. Secondary objectives were to assess pharmacokinetic and clinical activity and define the optimal dose for further clinical evaluation. In addition to clinical treatment parameters, cytokine levels were analyzed as an exploratory endpoint in the trial.

Shares of Idera closed Friday at $3.67, within a 52-week trading range of $2.27 to $5.48. The consensus analyst price target is $6.50. Over the course of the week, shares were up just below 10% to Thursday’s close, but the stock gave back more than 7% on Friday. Year to date, the stock is down 10%.